MML Investors Services
CPRX

MML Investors Services’s Catalyst Pharmaceutical CPRX Stock Holding History

MML Investors Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,495
Closed -$532K – 3266
2026
Q1 		$532K Buy
21,495
+8,287
+63% +$197K ﹤0.01% 2177
2025
Q4 		$308K Sell
13,208
-15,327
-54% -$341K ﹤0.01% 2600
2025
Q3 		$562K Buy
28,535
+5,924
+26% +$122K ﹤0.01% 2089
2025
Q2 		$491K Buy
+22,611
New +$534K ﹤0.01% 2109
2022
Q3 		– Sell
-11,621
Closed -$81K – 2090
2022
Q2 		$81K Buy
+11,621
New +$85.2K ﹤0.01% 1987

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MML Investors Services's CPRX Position: Q2 2026 in Review

MML Investors Services sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 21,495 shares — an estimated $532K sold.

MML Investors Services first reported a position in CPRX in Q2 2022 and held it in 5 quarters. The position peaked at $562K in Q3 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • MML Investors Services reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • MML Investors Services sold 21,495 Catalyst Pharmaceutical shares in Q2 2026, an estimated $532K.
  • MML Investors Services first reported a position in Catalyst Pharmaceutical in Q2 2022 and held it in 5 quarters.
  • MML Investors Services's Catalyst Pharmaceutical position peaked at $562K in Q3 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.